CLVT — what changed in the latest 10-Q
A section-by-section comparison of CLVT's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-11-03 vs the prior 10-Q · 2026-07-29
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +46 | −45 | ~49 | 102 |
| Market risk (Item 3) | Text added/removed | 0 | 0 | ~3 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~15 | 0 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | +7 | −3 | 0 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Legal proceedings
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-11-03
offer intelligence solutions, workflow solutions, and tech-enabled services to customers in the Academia & Government
(“A&G”) and Intellectual Property (“IP”) end markets, which form the basis of our reportable segment structure.
During the third quarter of 2026, we entered into a definitive commercial agreement to sell our Life Sciences & Healthcare
(“LS&H”) segment and concluded that the criteria for held-for-sale classification and discontinued operations presentation
were met as of September 30, 2026. Accordingly, the operating results of the LS&H segment have been reported as
Text removed vs the prior filing · source: 10-Q · 2026-07-29
by harnessing the power of human ingenuity. From research and learning to commercialization, we offer intelligence
solutions, workflow solutions, and tech-enabled services to customers in the Academia & Government (“A&G”), Intellectual
Property (“IP”), and Life Sciences & Healthcare (“LS&H”) end markets, which form the basis of our reportable segment
In July 2026, we announced that we entered into a definitive agreement to sell the LS&H business. We anticipate that the
transaction will close by the end of 2026, subject to customary closing conditions, including regulatory approvals and the
Other information
Text added vs the prior filing · source: 10-Q · 2026-11-03
On August 7, 2026, Bar Veinstein, President, Academia & Government, entered into a trading plan intended to satisfy the
affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The trading plan provides for the sale of an
aggregate of up to 254,558 ordinary shares of the Company held by Mr. Veinstein. The trading plan terminates on the earlier
of the date all the shares covered by the trading plan are sold and December 7, 2026.
On October 30, 2026, Saurabh Saha notified the Company of his resignation from the Board of Directors of the Company,
Text removed vs the prior filing · source: 10-Q · 2026-07-29
During the quarter ended June 30, 2026, no director or officer (as defined in Rule 16a-1 under the Exchange Act) of the
Company adopted or terminated a Rule 10b5-1 trading plan or adopted or terminated a non-Rule 10b5-1 trading arrangement
(as such terms are defined in Item 408(a) of Regulation S-K).
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice